Bioamber Inc (NYSE:BIOA) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Analysts have set a twelve-month consensus price target of $6.50 for the company and are predicting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Bioamber an industry rank of 151 out of 265 based on the ratings given to related companies.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Bioamber from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. ValuEngine cut shares of Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Cowen restated a “hold” rating and issued a $1.00 price objective on shares of Bioamber in a research report on Friday, November 10th.
Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its position in shares of Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 41,701 shares during the last quarter. Robecosam AG grew its position in Bioamber by 82.9% during the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 670,000 shares during the last quarter. Vanguard Group Inc. grew its position in Bioamber by 9.9% during the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after acquiring an additional 27,278 shares during the last quarter. Finally, FMR LLC grew its position in Bioamber by 1.9% during the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.
Shares of Bioamber (NYSE BIOA) opened at $0.45 on Friday. Bioamber has a 52-week low of $0.32 and a 52-week high of $5.93. The firm has a market capitalization of $23.19, a PE ratio of -0.64 and a beta of 2.65. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.